Table IV.
Comparison of weight changes between subgroups.
| Factors | Weight changes (mean ± SD, kg) | P-value |
|---|---|---|
| Age (years) | 0.027 | |
| ≤40 | 1.1±3.6 | |
| 40–50 | −0.3±4.5 | |
| ≥50 | −1.2±4.6 | |
| Weight (kg) | 0.013 | |
| ≤50 | 0.3±5.2 | |
| 50–60 | 1.3±3.5 | |
| ≥60 | −1.8±3.8 | |
| Menopausal status | 0.924 | |
| Premenopausal | −0.4±4.4 | |
| Postmenopausal | −0.5±5.5 | |
| Receptor status | 0.222 | |
| ER or PR+/HER2+ | −0.5±3.9 | |
| ER or PR+/HER2− | −1.2±4.9 | |
| ER or PR−/HER2+ | 0.9±3.1 | |
| ER or PR−/HER2− | −0.5±5.1 | |
| Stage | 0.231 | |
| I | −1.4±4.1 | |
| II | 0.5±4.4 | |
| III | −0.6±5.0 | |
| Chemotherapy regimens | 0.150 | |
| Anthracycline-based | −0.6±3.9 | |
| Anthracycline combined with taxane | −0.2±4.6 | |
| Chemotherapy cycles (no.) | 0.037 | |
| <4 | −1.5±4.6 | |
| ≥4 | 0.4±4.1 | |
| Hormone dosage (mg) | 0.038 | |
| ≤100 | −0.9±3.8 | |
| 100–200 | 0.5±5.1 | |
| ≥200 | 1.3±4.8 |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SD, standard deviation.